InflaRx N.V (IF0) - Cash Flow Conversion Efficiency
Based on the latest financial reports, InflaRx N.V (IF0) has a cash flow conversion efficiency ratio of -0.113x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.71 Million ≈ $-5.50 Million USD) by net assets (€41.56 Million ≈ $48.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See InflaRx N.V net asset quality index to measure how much of total assets are equity-financed.
InflaRx N.V - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how InflaRx N.V's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check IF0 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
InflaRx N.V Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of InflaRx N.V ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Prizma Pres Matbaacilik Yayincilik Sanayi ve Ticaret AS
IS:PRZMA
|
0.007x |
|
Siam Pan Group PCL
BK:SPG
|
0.014x |
|
Thac Mo Hydropower JSC
VN:TMP
|
0.122x |
|
Mondi Turkey Oluklui Mukavva Kagit ve Ambalaj Sanayi A.S.
IS:MNDTR
|
N/A |
|
Cornish Metals Inc.
V:CUSN
|
-0.014x |
|
TONGDAO LIEP.GR. DL-0001
F:6WT
|
N/A |
|
Midas Minerals Ltd
AU:MM1
|
-0.189x |
|
Pyrum Innovations AG
OL:PYRUM
|
-0.116x |
Annual Cash Flow Conversion Efficiency for InflaRx N.V (2016–2025)
The table below shows the annual cash flow conversion efficiency of InflaRx N.V from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see InflaRx N.V market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €41.56 Million ≈ $48.58 Million |
€-35.31 Million ≈ $-41.29 Million |
-0.850x | -7.48% |
| 2024-12-31 | €61.42 Million ≈ $71.80 Million |
€-48.56 Million ≈ $-56.77 Million |
-0.791x | -114.48% |
| 2023-12-31 | €102.58 Million ≈ $119.93 Million |
€-37.81 Million ≈ $-44.21 Million |
-0.369x | +3.49% |
| 2022-12-31 | €88.35 Million ≈ $103.29 Million |
€-33.74 Million ≈ $-39.45 Million |
-0.382x | -0.68% |
| 2021-12-31 | €105.28 Million ≈ $123.08 Million |
€-39.94 Million ≈ $-46.69 Million |
-0.379x | +19.14% |
| 2020-12-31 | €77.86 Million ≈ $91.03 Million |
€-36.53 Million ≈ $-42.70 Million |
-0.469x | -16.34% |
| 2019-12-31 | €107.15 Million ≈ $125.27 Million |
€-43.20 Million ≈ $-50.51 Million |
-0.403x | -183.28% |
| 2018-12-31 | €151.39 Million ≈ $176.99 Million |
€-21.55 Million ≈ $-25.19 Million |
-0.142x | -39.89% |
| 2017-12-31 | €119.43 Million ≈ $139.63 Million |
€-12.15 Million ≈ $-14.21 Million |
-0.102x | -152.36% |
| 2016-12-31 | €-25.69 Million ≈ $-30.03 Million |
€-4.99 Million ≈ $-5.84 Million |
0.194x | -- |
About InflaRx N.V
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinic… Read more